CO Ezugwu
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences
B Erdal
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences
D Chuck
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences
IA Khan
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences and Department of Pharmacognosy, School of Pharmacy, University of Mississippi, University, MS 38677, USA
CO Okunji
International Centre for Ethnomedicine and Drug Development, Nsukka Nigeria; and Bioresources Development & Conservation Programme 11303 Amherst Avenue Suite # 2, Silver Spring, MD 20902 USA and Division of Experimental Therapeutics, Walter Reed Army Inst
BM Schuster
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington DC, 20307-5100, USA
MM Iwu
International Centre for Ethnomedicine and Drug Development, Nsukka Nigeria; and Bioresources Development & Conservation Programme 11303 Amherst Avenue Suite # 2, Silver Spring, MD 20902 USA and Division of Experimental Therapeutics, Walter Reed Army Inst
Abstract
Three new indoloquinazolidine-type alkaloids, 2-methoxy-8-13-dihydro-7H-indolo[pyrido[2,1-b]quinazolin-5-one (1) , 2-methoxy-13-methyl-8-13-dihydro-7H-indolo[2',3',3,4]pyrido[2,1-b]quinazolin-5-one (2) , and 2-methoxy-14-methyl-7,8,13,14-tetrahydroindolo[2',3',4]pyrido[2,l-b]quinazolin-5-one (3) were isolated from Araliopsis tabouensis, together with three known compounds. The structures of the new compounds were determined primarily from 1D- and 2D-NMR spectroscopy. The antimalarial activities of compounds 1-5 were evaluated against Plasmodium falciparum D6 and W2 clones. The IC50 values in antimalarial bioassay for compounds 2-5 varied from 1.8 to 4.7 μg/ml.
Nig. J. Pharm. Res. 3(1) 2004: 42-48